Children's Hospital Oakland, Hematology/Oncology

Hematology/Oncology Department at UCSF Benioff Children's Hospital Oakland

Recent Faculty Publications (2012 - 2015)

Books:

PHO book
  • Hastings CA, Torkildson JC, Agrawal AK. Handbook of Pediatric Hematology and Oncology: Children's Hospital and Research Center Oakland. Second ed. West Sussex, United Kingdom: John Wiley & Sons, Ltd.; 2012. http://www.amazon.com/Handbook-Pediatric-Hematology-Oncology-Childrens/dp/0470670886.
  • Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guidelines for the Management of Non Tranfusion Dependent Thalassemia (NTDT). ed. Cyprus: Thalassemia International Federation; 2013. http://thalassemia.com/documents/NTDT-TIF-guidelines.pdf.
  • Vichinsky E, Levine L, Bhatia S, Bojanowski J, Coates T, Foote D, Fung E, Harmatz P, Jeng M, Knudsen J, Lal A, Pakbaz Z, Schroepfer C, Singer ST, Sweeters N, Walters M, Wood J. Standards of Care Guidelines for Thalassemia. Oakland, California: Children's Hospital & Research Center Oakland; 2012. http://hemonc.cho.org/thalassemia/documents/SOCGuidelines2012.pdf.
  • Vichinsky E, Levine L, Bhatia S, Bojanowski J, Coates T, Foote D, Fung E, Harmatz P, Jeng M, Knudsen J, Lal A, Pakbaz Z, Schroepfer C, Singer ST, Sweeters N, Walters M, Wood J. Standards of Care Guidelines for Thalassemia. Oakland, California: Children's Hospital & Research Center Oakland; 2015 (in process).

book: Emerging Therapies Targeting the Pathophysiology of Sickle Cell Disease book: Supportive Care in Pediatric Oncology

Edited Books:


Book Chapters:

  • Agrawal AK. Immunization Practice in Pediatric Oncology. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Agrawal AK, Feusner J. Supportive Care of Patients with Cancer. In: Lanzkowsky P, Lipton JM, Fish JD, eds. Manual of Pediatric Hematology and Oncology. 6th ed: Springer; 2015 (in press).
  • Agrawal AK, Hastings C, Feusner J. Knowledge Gaps and Opportunities for Research. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Agrawal AK, Hord JD. Hematopoietic Growth Factors. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Agrawal AK, Shah SS. Pediatrics. In: Gulati A, Puttanniah V, Byas-Smith M, eds. Essentials of Interventional Cancer Pain Management. New York: Springer; 2015 (in press).
  • Aguilar A, Agrawal AK, Feusner J. Hyperleukocytosis. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Ataga K, Vichinsky E. Thrombotic complications in sickle cell disease. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Chapter 122, Sixth (November 2012) ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012:p. 1445. http://books.google.com/books?id=_SVbYgEACAAJ&dq=9781608319060.
  • Chung JH, Agrawal AK, Swift PS. Acute Radiation Side Effects. In: Feusner J, Hastings CA, Agrawal AK, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • DeBaun M, Vichinsky E. Acute pain management in adults with sickle cell disease. In: Basow DS, ed. UpToDate. Topic 7144 Version 14.0; Oct, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/acute-pain-management-in-adults-with-sickle-cell-disease.
  • DeBaun M, Vichinsky E. Red blood cell transfusion in sickle cell disease. In: Basow DS, ed. UpToDate. Topic 90145 Version 8.0; Nov 11, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/red-blood-cell-transfusion-in-sickle-cell-disease.
  • DeBaun MR, Frei-Jones M, Vichinsky E. Sickle Cell Disease. In: Kliegman R, Stanton BF, St. Geme J, Schor N, Behrman, eds. Nelson Textbook of Pediatrics, Twentieth Edition. 462.1: Elsevier, Inc.; 2015 (in press).
  • Field J, Vichinsky E, DeBaun M. Overview of the management and prognosis of sickle cell disease. In: Basow DS, ed. UpToDate. Topic 7114 Version 37.0; Dec 01, 2014. Waltham, MD: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/overview-of-the-management-of-sickle-cell-disease.
  • Fung EB, Chung J. Nutrition for Children with Sickle Cell Disease and Thalassemia. In: Kleinman RE, Greer FR, eds. Pediatric Nutrition Handbook. 7th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2014:979-92. http://reader.aappublications.org/pediatric-nutrition-7th-edition-sponsored-member-benefit/2.
  • Garcia JR, Walters MC. Hematopoietic Cell Transplantation for non-malignant disorders. In: Greer J, 13th ed., ed. Wintrobe's Clinical Hematology. Philadelphia, PA: Wolwers Kluwer / Lippincott Williams & Wilkins; 2014.
  • Gomez E, Agrawal AK, Hastings C. Transfusion Support. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Khurana M, Su W. The Acute Abdomen. In: Feusner J, Hastings CA, Agrawal AK, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Berlin: Springer; 2015.
  • Lalefar NR, Lubin B. Sibling Donor Cord Blood Program: Children’s Hospital Research Center Oakland and Beyond. In: Dusko I, ed. Stem Cell Banking. New York, NY: Humana Press/Springer Science; 2014. http://www.amazon.com/Stem-Banking-Biology-Regenerative-Medicine/dp/1493905848.
  • Lo CY, Morris CR. Vasculopathy, Chronic Oxidative Stress and Endothelial Dysfunction in SCD. In: Acuña-Castroviejo D, Rusanova I, eds. Sickle Cell Disease: A New Vision for an Old Problem. Recent Advances in Hematology Research. Chapter 5; : Nova Science Publishers; 2013. https://www.novapublishers.co m/catalog/product_info.php?products_id=41344.
  • Marsh A, Agrawal AK, Feusner J. Tumor Lysis Syndrome. In: Agrawal AK, Hastings CH, Feusner J, eds. Supportive Care in Pediatric Oncology: A Practical Evidence-Based Approach. Chapter 3. Berlin: Springer; 2015.
  • Marsh A, Matsunaga A. Neonatal Alloimmune Thrombocytopenia. In: Cabana MD, ed. The 5-Minute Pediatric Consult. 7th ed: Lippincott Williams & Wilkins; 2014 (in press).
  • Marsh A, Vichinsky E. Sickle cell disease. In: Hoffbrand H, Higgs D, Keeling D, Mehta A, eds. Post Graduate Haematology, 7th edition. Wiley; 2015 (in press).
  • Morris CR. Arginine and Asthma. In: Makrides M, Ochoa JB, Szajewska H, eds. The Importance of Immunonutrition. Nestlé Nutrition Institute Workshop Series. Basel, Switzerland: Karger AG; 2013: pp 1-15 (DOI:0.1159/000351365). http://www.karger.com/Article/Abstract/351365.
  • Morris CR, Gladwin MT. Pulmonary hypertension in sickle cell disease and thalassemia. In: Naeije R, Rubin D, eds. Pulmonary Circulation. 4th ed. London, U.K.: Hodder Arnold; 2015 (in press).
  • Quirolo K, Vichinsky E. Sickle cell anemia, thalassemia, and other inherited hemolytic anemia In: Simon TL, McCullough J, Snyder E, Solheim BG, Strauss RG, eds. Rossi's Principles of Transfusion Medicine, 5th edition. Wiley; 2015 (in process).
  • Saunthararajah Y, Vichinsky EP. Sickle Cell Disease: Clinical Features and Management. In: Hoffman R, ed. Hematology: Basic Principles and Practice. Chapter 40, 6th ed. Philadelphia, PA: Saunders/Elsevier; 2013. http://uclibs.org/PID/62059
  • Vichinsky E. Overview of the clinical manifestations of sickle cell disease. In: Basow DS, ed. UpToDate. Topic 7119 Version 27.0; Nov. 24, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/overview-of-the-clinical-manifestations-of-sickle-cell-disease.
  • Vichinsky E. Pregnancy in women with sickle cell disease. In: Basow DS, ed. UpToDate. Topic 7139 Version 18.0; Sep 30, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/pregnancy-in-women-with-sickle-cell-disease.
  • Vichinsky E. Sickle Cell Syndromes. In: Decision Support in Medicine. http://decisionsupportinmedicine.com; 2013 (in process).
  • Vichinsky E. Sickle Cell Trait. In: Basow DS, ed. UpToDate. Topic 7145 Version 24.0; Nov 21 2014. www.UpToDate.com: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/sickle-cell-trait.
  • Vichinsky E. Variant Sickle Cell Syndromes. In: Basow DS, ed. UpToDate. Topic 7115 Version 11.0; March 28, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/variant-sickle-cell-syndromes.
  • Vichinsky E, Mahoney DH. Diagnosis of sickle cell disorders. In: Basow DS, ed. UpToDate. Topic 7113 Version 15.0; Aug 28, 2014. Waltham, MA: UpToDate, Inc.; 2014. http://www.uptodate.com/contents/diagnosis-of-sickle-cell-syndromes.
  • Walters MC. Hematopoietic cell transplantation for sickle cell disease. In: Forman SJ, Negris RS, Antin J, Applebaum FR, eds. Hematopoietic Cell Transplantation. Fifth ed. Malden, MA: Blackwell Science; 2014 (in press).

Journal Articles:

  • Adam SS, Hoppe C. Potential role for statins in sickle cell disease. Pediatr Blood Cancer 2013;60 4:60;4 p.550-7. http://www.ncbi.nlm.nih.gov/pubmed/23281161.
  • Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol 2014;50 6:625-9. http://www.ncbi.nlm.nih.gov/pubmed/24742799.
  • Afshar M, Golden C. Report of neuroblastoma in a set of monozygotic monochorionic twins. Pediatr Hematol Oncol 2013;30 4:285-7. http://www.ncbi.nlm.nih.gov/pubmed/23373760.
  • Afzal SY, Wender AR, Jones MD, Fung EB, Pico EL. The effect of low magnitude mechanical stimulation (LMMS) on bone density in patients with Rett syndrome: a pilot and feasibility study. J Pediatr Rehabil Med 2014;7 2:167-78. http://www.ncbi.nlm.nih.gov/pubmed/25096869.
  • Agrawal AK, Hsu E, Quirolo K, Neumayr LD, Flori HR. Red blood cell transfusion in pediatric patients with severe chronic anemia: how slow is necessary? Pediatr Blood Cancer 2012;58 3:466-8. http://www.ncbi.nlm.nih.gov/pubmed/21793178.
  • Agrawal AK, Kammen BF, Guo H, Donthineni R. An unusual presentation of subcutaneous granuloma annulare in association with juvenile-onset diabetes: case report and literature review. Pediatr Dermatol 2012;29 2:202-5. http://www.ncbi.nlm.nih.gov/pubmed/22085091.
  • Aguilar A, Saba JD. Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 2012;52 1:17-30. http://www.ncbi.nlm.nih.gov/pubmed/21946005.
  • Amstrong D, Neumayr L, Gold JI, Weiner MW, Rule RR, LeBeau P, Kesler K, McMahon L, Orringer EP, Harrington T, DeCastro LM, Kalinyak K, Kutlar A, Rutherford CJ, Johnson C, Bessman JD, Hussein A, Vichinsky EP. Biologic predictors of memory, attention, and executive function in neurologically asymptomatic adults with sickle cell anemia. 2014 (submitted).
  • Anglemyer A, Agrawal AK, Rutherford GW. Treatment of Kaposi sarcoma in children with HIV-1 infection. Cochrane Database Syst Rev 2014;1:CD009826. http://www.ncbi.nlm.nih.gov/pubmed/24464843.
  • Bae HT, Baldwin CT, Sebastiani P, Telen MJ, Ashley-Koch A, Garrett M, Hooper WC, Bean CJ, Debaun MR, Arking DE, Bhatnagar P, Casella JF, Keefer JR, Barron-Casella E, Gordeuk V, Kato GJ, Minniti C, Taylor J, Campbell A, Luchtman-Jones L, Hoppe C, Gladwin MT, Zhang Y, Steinberg MH. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 2012;120 9:1961-2. http://www.ncbi.nlm.nih.gov/pubmed/22936743.
  • Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal 2012;2012:949535. http://www.ncbi.nlm.nih.gov/pubmed/22924029.
  • Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Erratum to "Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management". ScientificWorldJournal 2013;2013:861251. http://www.ncbi.nlm.nih.gov/pubmed/23483854.
  • Ballas SK, Vichinsky E. Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or An Illusion? . Hemoglobin 2015 (in press).
  • Behera RK, Theil EC. Moving Fe2+ from ferritin ion channels to catalytic OH centers depends on conserved protein cage carboxylates. Proc Natl Acad Sci U S A 2014;111 22:7925-30. http://www.ncbi.nlm.nih.gov/pubmed/24843174.
  • Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012;52 7:1517-22. http://www.ncbi.nlm.nih.gov/pubmed/22168221.
  • Chen Q, Fabry ME, Rybicki AC, Suzuka SM, Balazs TC, Etzion Z, de Jong K, Akoto EK, Canterino JE, Kaul DK, Kuypers FA, Lefer D, Bouhassira EE, Hirsch RE. A transgenic mouse model expressing exclusively human hemoglobin E: indications of a mild oxidative stress. Blood Cells Mol Dis 2012;48 2:91-101. http://www.ncbi.nlm.nih.gov/pubmed/22260787.
  • Chokkalingam AP, Metayer C, Scelo G, Chang JS, Schiffman J, Urayama KY, Ma X, Hansen HM, Feusner JH, Barcellos LF, Wiencke JK, Wiemels JL, Buffler PA. Fetal growth and body size genes and risk of childhood acute lymphoblastic leukemia. Cancer Causes Control 2012;23 9:1577-85. http://www.ncbi.nlm.nih.gov/pubmed/22878902.
  • Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer 2012;118 3:761-9. http://www.ncbi.nlm.nih.gov/pubmed/21766293.
  • Cui J, Azimi M, Adekile AD, Al Awadhi H, Hoppe CC. Detection of anti-Lepore Hb P-Nilotic by multiplex ligation-dependent probe amplification. Hemoglobin 2012;36 3:276-82. http://www.ncbi.nlm.nih.gov/pubmed/22384950.
  • Cui J, Azimi M, Baysdorfer C, Vichinsky EP, Hoppe CC. Application of multiplex ligation-dependent probe amplification to screen for beta-globin cluster deletions: detection of two novel deletions in a multi ethnic population. Hemoglobin 2013;37 3:241-56. http://www.ncbi.nlm.nih.gov/pubmed/23577918.
  • Cui J, Azimi M, Hoppe CC. Detection of a novel betadelta-globin fusion gene, anti-lepore Hb CHORI (beta(through IVS-I-57)/delta(from IVS-I-101)), by multiplex ligation-dependent probe amplification. Hemoglobin 2014;38 1:60-3. http://www.ncbi.nlm.nih.gov/pubmed/24102354.
  • Cui J, Baysdorfer C, Azimi M, Vichinsky EP, Hoppe CC. Identification of three novel Hb F variants: Hb F-Hayward [Ggamma1(NA1)Gly-->Asp, GGT>GAT], Hb F-Chori-I [AgammaT16(A13)Gly-->Asp, GGC>GAC] and Hb F-Chori-II [AgammaI29(B11)Gly-->Glu, GGA>GAA]. Hemoglobin 2012;36 3:305-9. http://www.ncbi.nlm.nih.gov/pubmed/22384921.
  • Dagri JN, Evans A, Torkildson JC, Portnow J, Ashby LS, Zakotnik B, Brown RJ, Dhall G, Finlay JL. Feasibility of an Attenuated Maintenance chemotherapy Regimen Directed at Adolescents and Young Adults with Newly Diagnosed Localized Medulloblastoma and Other Central Nervous System Embryonal Tumors. J Adolescent and Young Adult Oncology 2014;3 3:106-11.
  • Dang DN, Morris HD, Feusner JH, Koduru P, Wilson K, Timmons CF, Cavalier M, Luu HS. Therapy-induced Secondary Acute Myeloid Leukemia With t(11;19)(q23;p13.1) in a Pediatric Patient With Relapsed Acute Promyelocytic Leukemia. J Pediatr Hematol Oncol 2014;36 8:e546-8. http://www.ncbi.nlm.nih.gov/pubmed/24942021.
  • Day LL, Murray E, Treadwell MJ, Lubin BH. Teaching about Genetics and Sickle Cell Disease in Fifth Grade. Journal of the National Medical Association 2015 (in press).
  • DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119 20:4587-96. http://www.ncbi.nlm.nih.gov/pubmed/22354000.
  • Delgado EM, Cho CS, Gildengorin G, Leibovich SA, Morris CR. Parental Asthma Education and Risks for Nonadherence to Pediatric Asthma Treatments. Pediatr Emerg Care 2014;30 11:782-7 10.1097/PEC.0000000000000259. http://journals.lww.com/pec-online/Fulltext/2014/11000/Parental_Asthma_Education_and_Risks_for.3.aspx
  • Doh I, Lee WC, Cho YH, Pisano AP, Kuypers FA. Deformation measurement of individual cells in large populations using a single-cell microchamber array chip. Appl Phys Lett 2012;100 17:173702-1737023. http://www.ncbi.nlm.nih.gov/pubmed/22586355.
  • Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman MS. All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. Leuk Res 2013. http://www.ncbi.nlm.nih.gov/pubmed/23528262.
  • Dror DK, King JC, Durand DJ, Fung EB, Allen LH. Feto-maternal vitamin D status and infant whole-body bone mineral content in the first weeks of life. Eur J Clin Nutr 2012;66 9:1016-9. http://www.ncbi.nlm.nih.gov/pubmed/22781021.
  • Dror DK, King JC, Fung EB, Van Loan MD, Gertz ER, Allen LH. Evidence of associations between feto-maternal vitamin D status, cord parathyroid hormone and bone-specific alkaline phosphatase, and newborn whole body bone mineral content. Nutrients 2012;4 2:68-77. http://www.ncbi.nlm.nih.gov/pubmed/22413062.
  • Fens MH, Larkin SK, Oronsky B, Scicinski J, Morris CR, Kuypers FA. The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions. PLoS One 2014;9 7:e101626. http://www.ncbi.nlm.nih.gov/pubmed/25007272.
  • Flanagan JM, Sheehan V, Linder H, Howard TA, Wang YD, Hoppe CC, Aygun B, Adams RJ, Neale GA, Ware RE. Genetic mapping and exome sequencing identify two mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood 2013. http://www.ncbi.nlm.nih.gov/pubmed/23422753.
  • Fung EB, Gariepy CA, Sawyer AJ, Higa A, Vichinsky EP. The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. Am J Hematol 2012;87 10:E76-9. http://www.ncbi.nlm.nih.gov/pubmed/22886910.
  • Fung EB, Kwiatkowski JL, Huang JN, Gildengorin G, King JC, Vichinsky EP. Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2013;98 4:960-71. http://www.ncbi.nlm.nih.gov/pubmed/23945720.
  • Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP, Thalassemia Clinical Research N. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet 2012;112 7:980-90. http://www.ncbi.nlm.nih.gov/pubmed/22551675.
  • Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W. Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 2012;120 10:2098-108. http://www.ncbi.nlm.nih.gov/pubmed/22734072.
  • Garcia JR, Pollard J, Thomson B. Minimal Residual Disease in Acute Leukemias: review of literature and introduction of “bridging therapy” prior to hematopoietic cell transplantation. 2014 (submitted).
  • Gardner K, Hoppe C, Mijovic A, Vichinsky E, Thein SL. How we treat delayed hemolytic transfusion reactions in patients with sickle cell disease. 2015 (in process).
  • Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JGt, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF, Walk Phaast investigators. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PloS one. 2014;9(7):e99489. Epub 2014/07/06. doi: 10.1371/journal.pone.0099489. PubMed PMID: 24988120; PubMed Central PMCID: PMC4079316. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0099489.
  • Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer 2013;60 9:1507-12. http://www.ncbi.nlm.nih.gov/pubmed/23637051.
  • Gomez E, Morris CR. Asthma Management in Sickle Cell Disease. Biomed Res Int 2013;2013:604140. http://www.ncbi.nlm.nih.gov/pubmed/24324967.
  • Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS One 2013;8 2:e55709. http://www.ncbi.nlm.nih.gov/pubmed/23409025.
  • Green ST, Martin MB, Haines D, Carson S, Coates T, Oliveros O, Gerstenberger E, Trachtenberg F, Kwiatkowski JL, Thalassaemia Clinical Research N. Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol 2014;166 5:797-800. http://www.ncbi.nlm.nih.gov/pubmed/24805301.
  • Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, Feusner JH, Shamberger RC, Green DM, Breslow NE. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol 2012;27 8:1325-33. http://www.ncbi.nlm.nih.gov/pubmed/22430485.
  • Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T, Eile J, Schilling L, Dinu B, Mendoza T, Gerstenberger E, Trachtenberg F, Vichinsky E, Thalassemia Clinical Research N. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013;160 5:680-7. http://www.ncbi.nlm.nih.gov/pubmed/23278768.
  • Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M, Seibel NL. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (>/=200 x 10 /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. Br J Haematol 2014. http://www.ncbi.nlm.nih.gov/pubmed/25308804.
  • Hoppe CC. Prenatal and newborn screening for hemoglobinopathies. Int J Lab Hematol 2013;35 3:297-305. http://www.ncbi.nlm.nih.gov/pubmed/23590658.
  • Hoppe CC. Inflammatory mediators of endothelial injury in sickle cell disease. Hematol Oncol Clin North Am 2014;28 2:265-86. http://www.ncbi.nlm.nih.gov/pubmed/24589266.
  • Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI. Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metallomics 2013. http://www.ncbi.nlm.nih.gov/pubmed/24343124.
  • Jacobs JE. Invasive aspergillus Infections in Hospitalized Pediatric Oncology Patients. 2014 (submitted).
  • Johnson KJ, Williams KS, Ross JA, Krailo MD, Tomlinson GE, Malogolowkin MH, Feusner JH, Spector LG. Parental tobacco and alcohol use and risk of hepatoblastoma in offspring: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev 2013;22 10:1837-43. http://www.ncbi.nlm.nih.gov/pubmed/23950215.
  • Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012;18 8:1265-72. http://www.ncbi.nlm.nih.gov/pubmed/22343376.
  • Kanathezhath B, Suh J, Guo H, Ho J, Siu K, Gieng J, Bhandal M, Ali A, Kuypers F, Walters AM, Ames B. Defective Host Nrf2 function contributes to heightened oxidative stress and correlates with disease severity in experimental graft versus host disease. Biology of Blood and Marrow Transplantation 2014 (in press).
  • Kanathezhath B, Shenvi S, Johl A, Manmohan R, Bhandhal MK, Oh D, Zhou A, Kuypers FA, Walters MC, Ames BN, Suh J. Systemic and Hepatic Thiol Redox Dysregulation in Graft Versus Host Disease. Biology of blood and marrow transplantation: Journal of the American Society for Blood and Marrow Transplantation 2012;18 2:S359-S60. http://linkinghub.elsevier.com/retrieve/pii/S1083879111009748?showall=true.
  • Karafin MS, Graminske S, Erickson P, Walters MC, Scott EP, Carter S, Padmanabhan A. Evaluation of the Spectra Optia apheresis system for mononuclear cell (MNC) collection in G-CSF mobilized and nonmobilized healthy donors: results of a multicenter study. J Clin Apher 2014;29 5:273-80. http://www.ncbi.nlm.nih.gov/pubmed/24677347.
  • Karski EE, Dvorak CC, Leung W, Miller W, Shaw PJ, Qayed M, Katsanis E, Feusner JH. Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue: The Pediatric Blood and Marrow Transplant Consortium Experience and Review of the Literature. J Pediatr Hematol Oncol 2014. http://www.ncbi.nlm.nih.gov/pubmed/24577552.
  • Kato GJ, Vichinsky E, Galacteros F, Weatherall D, Costa F, Ohene-Frempong K, Krishnamurti L, Smith W, Panepinto J. Sickle Cell Disease for Basic Scientists. Nature Reviews 2015 (in process).
  • Keller SD, Yang M, Treadwell MJ, Werner EM, Hassell KL. Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks. Health Qual Life Outcomes 2014;12:125. http://www.ncbi.nlm.nih.gov/pubmed/25146160.
  • Khurana M, Fung EB, Vichinsky E, Theil EC. Dietary ferritin iron, equally bioavailable to non-heme ferrous iron, may be safely consumed in thalassemia intermedia with risk for iron overload. Am J Clin Nutr 2015 (submitted).
  • Klaassen RJ, Barrowman N, Merelles-Pulcini M, Vichinsky EP, Sweeters N, Kirby-Allen M, Neufeld EJ, Kwiatkowski JL, Wu J, Vickars L, Blanchette VS, Forgie M, Yamashita R, Wong-Rieger D, Young NL. Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major. Br J Haematol 2014;164 3:431-7. http://www.ncbi.nlm.nih.gov/pubmed/24180641.
  • Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT, American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell D. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727-40. Epub 2014/03/19. doi: 10.1164/rccm.201401-0065ST. PubMed PMID: 24628312; PubMed Central PMCID: PMC3983842.
  • Kutlar A, Ataga K, Reid M, Vichinsky EP, Neumayr L, Blair-Britt L, Labotka R, Glass J, Keefer JR, Wargin WA, Berenson R, Perrine SP. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2012;87 11:1017-21. http://www.ncbi.nlm.nih.gov/pubmed/22887019.
  • Kutlar A, Ataga KI, McMahon L, Howard J, Galacteros F, Hagar W, Vichinsky E, Cheung AT, Matsui N, Embury SH. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012;87 5:536-9. http://www.ncbi.nlm.nih.gov/pubmed/22488107.
  • Kutny MA, Gregory J, Jr., Feusner JH. Treatment of paediatric APL: how does the therapeutic approach differ from adults? Best Pract Res Clin Haematol 2014;27 1:69-78. http://www.ncbi.nlm.nih.gov/pubmed/24907019.
  • Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012;59 4:662-7. http://www.ncbi.nlm.nih.gov/pubmed/22378655.
  • Kuypers FA. Hemoglobin S Polymerization and Red Cell Membrane Changes. Hematol Oncol Clin North Am 2014;28 2:155-79. http://www.ncbi.nlm.nih.gov/pubmed/24589260.
  • Kuypers FA, Marsh AM. Research in athletes with sickle cell trait: just do it. J Appl Physiol 2012;112 9:1433. http://www.ncbi.nlm.nih.gov/pubmed/22362400.
  • Kwiatkowski J, Kim HY, Thompson A, Quinn C, Mueller B, Odame I, Giardina P, Vichinsky E, Boudreaux JM, Porter J, Coates T, Olivieri N, Neufeld E. Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century. 2014 (submitted).
  • Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research N. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012;119 12:2746-53. http://www.ncbi.nlm.nih.gov/pubmed/22279056.
  • Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis 2013;50 2:99-104. http://www.ncbi.nlm.nih.gov/pubmed/23151373.
  • Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, Vermylen C, Dalle JH, Stein J, Wynn R, Cordonnier C, Pinto F, Angelucci E, Socie G, Gluckman E, Walters MC, Rocha V, Eurocord, European B, Marrow Transplantation g. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013;122 6:1072-8. http://www.ncbi.nlm.nih.gov/pubmed/23692854.
  • Mackin RS, Insel P, Truran D, Vichinsky EP, Neumayr LD, Armstrong FD, Gold JI, Kesler K, Brewer J, Weiner MW, Neuropsychological D, Neuroimaging Adult Sickle Cell Anemia Study G. Neuroimaging abnormalities in adults with sickle cell anemia: associations with cognition. Neurology 2014;82 10:835-41. http://www.ncbi.nlm.nih.gov/pubmed/24523480.
  • Marsh A, Golden C, Hoppe C, Quirolo K, Vichinsky E. Renal medullary carcinoma in an adolescent with sickle cell anemia. Pediatr Blood Cancer 2014;61 3:567. http://www.ncbi.nlm.nih.gov/pubmed/24108577.
  • Marsh A, Schiffelers R, Kuypers F, Larkin S, Gildengorin G, van Solinge W, Hoppe C. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease. Br J Haematol 2015;168 1:135-8. http://www.ncbi.nlm.nih.gov/pubmed/25196812.
  • Marsh A, Vichinsky E. Alpha Thalassemia and Hydrops Fetalis. 2014 (in process).
  • Marsh AM, Lo L, Cohen RA, Feusner JH. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatr Blood Cancer 2012;59 5:939-40. http://www.ncbi.nlm.nih.gov/pubmed/22492703.
  • Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Mansson JE, Blomqvist M, Gobom J, Andreasson U, Brinkmalm G, Vite C, Hecimovic S, Hastings C, Blennow K, Zetterberg H, Portelius E. Amyloid-beta metabolism in Niemann-Pick C disease models and patients. Metab Brain Dis 2012;27 4:573-85. http://www.ncbi.nlm.nih.gov/pubmed/22935999.
  • Mietus-Snyder ML, Shigenaga MK, Suh JH, Shenvi SV, Lal A, McHugh T, Olson D, Lilienstein J, Krauss RM, Gildengoren G, McCann JC, Ames BN. A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial. FASEB J 2012;26 8:3515-27. http://www.ncbi.nlm.nih.gov/pubmed/22549511.
  • Milton JN, Rooks H, Drasar E, McCabe EL, Baldwin CT, Melista E, Gordeuk VR, Nouraie M, Kato GR, Minniti C, Taylor J, Campbell A, Luchtman-Jones L, Rana S, Castro O, Zhang Y, Thein SL, Sebastiani P, Gladwin MT, Walk-Phaast-Investigators, Steinberg MH. Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol 2013;161 2:270-8. http://www.ncbi.nlm.nih.gov/pubmed/23406172.
  • Morris CR, Kim H, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri N, Kwiatkowski J, Singer ST, Taher A, Neufeld E, Thompson AA, Sachdev V, Larken S, Suh JH, Kuypers FA, Vichinsky EP, Thalassemia-Clinical-Research-Network. Alterations in the arginine metabolome and cardiopulmonary dysfunction in patients with thalassemia. British Journal of Haematology 2015 (under review).
  • Morris CR. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. Hematol Oncol Clin North Am 2014;28 2:301-21. http://www.ncbi.nlm.nih.gov/pubmed/24589268.
  • Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP, Thalassemia Clinical Research N. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 2013;98 9:1359-67. http://www.ncbi.nlm.nih.gov/pubmed/23585527.
  • Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, Gildengorin G, Neumayr L, Vichinsky EP. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013;98 9:1375-82. http://www.ncbi.nlm.nih.gov/pubmed/23645695.
  • Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013;98 6:833-44. http://www.ncbi.nlm.nih.gov/pubmed/23729725.
  • Musselman JR, Georgieff MK, Ross JA, Tomlinson GE, Feusner J, Krailo M, Spector LG. Maternal pregnancy events and exposures and risk of hepatoblastoma: A Children's Oncology Group (COG) study. Cancer Epidemiol 2013. http://www.ncbi.nlm.nih.gov/pubmed/23312454.
  • Nazarov I, Lee JW, Soupene E, Etemad S, Knapik D, Green W, Bashkirova E, Fang X, Matthay MA, Kuypers FA, Serikov VB. Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. Stem Cells Transl Med 2012;1 5:359-72. http://www.ncbi.nlm.nih.gov/pubmed/23197815.
  • Nouraie M, Barst R, Kato GJ, Gibbs JS, Sachdev V, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JGt, Goldsmith JC, Gladwin MT, Gordeuk V, Walk_Phasst_Investigators. NT-pro BNP is a biomarker of both right and left cardiac function in patients with sickle cell disease: Insights from Walk-PHaSST. Blood 2014 (under review).
  • Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT, Walk PI, Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2013;98 3:464-72. http://www.ncbi.nlm.nih.gov/pubmed/22983573.
  • Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S, Green S, Calamaras D, Hess P, Yamashita R, Vichinsky E, Thalassemia Clinical Research N. Pain over time and its effects on life in thalassemia. Am J Hematol 2013;88 11:939-43. http://www.ncbi.nlm.nih.gov/pubmed/23918696.
  • Orgel E, Zung L, Ji L, Finklestein J, Feusner J, Freyer DR. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer 2013;60 9:1528-33. http://www.ncbi.nlm.nih.gov/pubmed/23441080.
  • Paulukonis ST, Harris WT, Coates TD, Neumayr L, Treadwell M, Vichinsky E, Feuchtbaum LB. Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer 2014;61 12:2271-6. http://www.ncbi.nlm.nih.gov/pubmed/25176145.
  • Perilongo G, Malogolowkin M, Feusner J. Hepatoblastoma clinical research: Lessons learned and future challenges. Pediatric Blood & Cancer 2012;59 5:818-21. http://dx.doi.org/10.1002/pbc.24217.
  • Polgreen LE, Thomas W, Fung E, Viskochil D, Stevenson DA, Steinberger J, Orchard P, Whitley CB, Ensrud KE. Low Bone Mineral Content and Challenges in Interpretation of Dual-Energy X-Ray Absorptiometry in Children With Mucopolysaccharidosis Types I, II, and VI. J Clin Densitom 2014;17 1:200-6. http://www.ncbi.nlm.nih.gov/pubmed/23562131.
  • Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, Weyhmiller MG, Harmatz PR, Wood JC, Miller JL, Byrnes C, Weiss G, Seifert M, Grosse R, Grabowski D, Schmidt A, Fischer R, Nielsen P, Niemeyer C, Vichinsky E. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Br J Haematol 2014;167 5:692-6. http://www.ncbi.nlm.nih.gov/pubmed/25209728.
  • Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 2013;15 1:38. http://www.ncbi.nlm.nih.gov/pubmed/23688265.
  • Pratini NR, Sweeters N, Vichinsky E, Neufeld JA. Treatment of Classic Pantothenate Kinase-Associated Neurodegeneration with Deferiprone and Intrathecal Baclofen. Am J Phys Med Rehabil 2013. http://www.ncbi.nlm.nih.gov/pubmed/23370589.
  • Puumala SE, Ross JA, Feusner JH, Tomlinson GE, Malogolowkin MH, Krailo MD, Spector LG. Parental infertility, infertility treatment and hepatoblastoma: a report from the Children's Oncology Group. Hum Reprod 2012;27 6:1649-56. http://www.ncbi.nlm.nih.gov/pubmed/22473396.
  • Qayed M, Khurana M, Hilinski J, Gillespie S, McCracken C, Applegate K, Chiang K-Y, Horan J. Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2015;62 2:364-6. http://dx.doi.org/10.1002/pbc.25237.
  • Quirolo K, Bertolone S, Hassell K, Howard T, King KE, Rhodes DK, Bill J. The evaluation of a new apheresis device for automated red blood cell exchange procedures in patients with sickle cell disease. Transfusion 2014. http://www.ncbi.nlm.nih.gov/pubmed/25330984.
  • Reid ME, Halter Hipsky C, Hue-Roye K, Hoppe C. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis 2014;52 4:195-202. http://www.ncbi.nlm.nih.gov/pubmed/24309423.
  • Romero Z, Urbinati F, Geiger S, Cooper AR, Wherley J, Kaufman ML, Hollis RP, de Assin RR, Senadheera S, Sahagian A, Jin X, Gellis A, Wang X, Gjertson D, Deoliveira S, Kempert P, Shupien S, Abdel-Azim H, Walters MC, Meiselman HJ, Wenby RB, Gruber T, Marder V, Coates TD, Kohn DB. Beta-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest 2013. http://www.jci.org/articles/view/67930.
  • Singer ST, Kuypers F, Fineman J, Gildengorin G, Larkin S, Sweeters N, Rosenfeld H, Kurio G, Higa A, Jeng M, Huang J, Vichinsky EP. Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. Ann Hematol 2014;93 7:1139-48. http://www.ncbi.nlm.nih.gov/pubmed/24577514.
  • Smith S, Witkowski A, Moghul A, Yoshinaga Y, Nefedov M, de Jong P, Feng D, Fong L, Tu Y, Hu Y, Young SG, Pham T, Cheung C, Katzman SM, Brand MD, Quinlan CL, Fens M, Kuypers F, Misquitta S, Griffey SM, Tran S, Gharib A, Knudsen J, Hannibal-Bach HK, Wang G, Larkin S, Thweatt J, Pasta S. Compromised mitochondrial fatty acid synthesis in transgenic mice results in defective protein lipoylation and energy disequilibrium. PLoS One 2012;7 10:e47196. http://www.ncbi.nlm.nih.gov/pubmed/23077570.
  • Sohn EY, Kato R, Noetzli LJ, Gera A, Coates T, Harmatz P, Keens TG, Wood JC. Exercise performance in thalassemia major: Correlation with cardiac iron burden. Am J Hematol 2013;88 3:193-7. http://www.ncbi.nlm.nih.gov/pubmed/23339082.
  • Soni S, Boulad F, Cowan MJ, Scaradavou A, Dahake J, Edwards S, Walters MC. Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies. Pediatr Blood Cancer 2014;61 9:1690-4. http://www.ncbi.nlm.nih.gov/pubmed/24803091.
  • Soupene E, Kuypers FA. Phosphatidylcholine formation by LPCAT1 is regulated by Ca(2+) and the redox status of the cell. BMC Biochem 2012;13:8. http://www.ncbi.nlm.nih.gov/pubmed/22676268.
  • Soupene E, Rothschild J, Kuypers FA, Dean D. Eukaryotic protein recruitment into the Chlamydia inclusion: implications for survival and growth. PLoS One 2012;7 5:e36843. http://www.ncbi.nlm.nih.gov/pubmed/22590624.
  • Stevenson DA, Rudser K, Kunin-Batson A, Fung EB, Viskochil D, Shapiro E, Orchard PJ, Whitley CB, Polgreen LE. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med 2014;7 2:159-65. http://www.ncbi.nlm.nih.gov/pubmed/25096868.
  • Stookey JD, Klein A, Hamer J, Chi C, Higa A, Ng V, Arieff A, Kuypers FA, Larkin S, Perrier E, Lang F. RBC deformability and amino acid concentrations after hypo-osmotic challenge may reflect chronic cell hydration status in healthy young men. Physiol Rep 2013;1 5:e00117. http://www.ncbi.nlm.nih.gov/pubmed/24303184.
  • Suh J, Kanathezhath B, Shenvi S, Guo H, Zhou A, Tiwana A, Kuypers F, Ames B, Walters M. Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD). PLoS ONE 2014;9 (2):e88868. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0088868.
  • Switzer WM, Shankar A, Trimble SR, Thompson AA, Giardina PJ, Cohen AR, Coates TD, Vichinsky E, Neufeld EJ, Boudreaux JM, Heneine W. Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Res Hum Retroviruses 2013. http://www.ncbi.nlm.nih.gov/pubmed/23409829.
  • Tang H, Ho H, Wu P, Chen S, Kuypers FA, Cheng M, Chiu DT. Inability to Maintain GSH Pool in G6PD-Deficient Red Cells Causes Futile AMPK Activation and Irreversible Metabolic Disturbance. Antioxid Redox Signal 2015. http://www.ncbi.nlm.nih.gov/pubmed/25556665.
  • Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A biopsychosocial-spiritual model of chronic pain in adults with sickle cell disease. Pain Manag Nurs 2013;14 4:287-301. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857562/.
  • Te Vruchte D, Speak AO, Wallom KL, Al Eisa N, Smith DA, Hendriksz CJ, Simmons L, Lachmann RH, Cousins A, Hartung R, Mengel E, Runz H, Beck M, Amraoui Y, Imrie J, Jacklin E, Riddick K, Yanjanin NM, Wassif CA, Rolfs A, Rimmele F, Wright N, Taylor C, Ramaswami U, Cox TM, Hastings C, Jiang X, Sidhu R, Ory DS, Arias B, Jeyakumar M, Sillence DJ, Wraith JE, Porter FD, Cortina-Borja M, Platt FM. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest 2014. http://www.ncbi.nlm.nih.gov/pubmed/24487591.
  • Theil EC. IRE mRNA riboregulators use metabolic iron (Fe) to control mRNA activity and iron chemistry in animals. Metallomics 2014. http://www.ncbi.nlm.nih.gov/pubmed/25209685.
  • Thompson AA, Kim HY, Singer ST, Vichinsky E, Eile J, Yamashita R, Giardina PJ, Olivieri N, Parmar N, Trachtenberg F, Neufeld EJ, Kwiatkowski JL, Thalassemia Clinical Research N. Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. Am J Hematol 2013;88 9:771-3. http://www.ncbi.nlm.nih.gov/pubmed/23757266.
  • Tolar J, Mehta PA, Walters MC. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant 2012;18 1 Suppl:S166-71. http://www.ncbi.nlm.nih.gov/pubmed/22226101.
  • Trachtenberg F, Haines D, Oliveros O. Design and Implementation of a Study to Assess Pain in Thalassemia. 2014 (in process).
  • Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, Thompson AA, Neufeld EJ, Yamashita R, Thalassemia Clinical Research N. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res 2014;23 8:2277-88. http://www.ncbi.nlm.nih.gov/pubmed/24682717.
  • Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R, Thalassemia Clinical Research N. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes 2012;10:148. http://www.ncbi.nlm.nih.gov/pubmed/23216870.
  • Treadwell MJ, Anie KA, Grant AM, Ofori-Acquah SF, Ohene-Frempong K. Using Formative Research to Develop a Counselor Training Program for Newborn Screening in Ghana. J Genet Couns 2014. http://www.ncbi.nlm.nih.gov/pubmed/25193810.
  • Treadwell MJ, Barreda F, Kaur K, Gildengorin G. Emotional distress, barriers to care and health-related quality of life in sickle cell disease. J Clin Outcomes Manage 2015 (in press).
  • Treadwell MJ, Bell M, Leibovich SA, Barreda F, Marsh A, Gildengorin G, Morris CR. A Quality Improvement Initiative to Improve Emergency Department Care for Pediatric Patients with Sickle Cell Disease. J Clin Outcomes Manage 2014;21 2:62-70. http://www.hospitalphysician.com/pdf/jcom_feb14_pediatric.pdf.
  • Treadwell MJ, Hassell K, Levine R, Keller S. Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me): Conceptual Model Based on Review of the Literature and Formative Research. Clin J Pain 2014. http://www.ncbi.nlm.nih.gov/pubmed/24300219.
  • Trimble S, Reyes N, Thompson A, Giardina P, Cohen A, Coates T, Vichinsky E, Neufeld E, Boudreaux J, Miller C, Grant A. Viral Seroconversion Monitoring in Chronically Transfused Thalassemia Patients in the United States, 2004-2009. 2014 (in process).
  • Trobaugh-Lotrario AD, Chaiyachati BH, Meyers RL, Haberle B, Tomlinson GE, Katzenstein HM, Malogolowkin MH, von Schweinitz D, Krailo M, Feusner JH. Outcomes for patients with congenital hepatoblastoma. Pediatr Blood Cancer 2013;60 11:1817-25. http://www.ncbi.nlm.nih.gov/pubmed/23798361.
  • Trobaugh-Lotrario AD, Feusner JH. Relapsed hepatoblastoma. Pediatric Blood & Cancer 2012;59 5:813-7. http://dx.doi.org/10.1002/pbc.24218.
  • Trobaugh-Lotrario AD, Venkatramani R, Feusner JH. Hepatoblastoma in Children With Beckwith-Wiedemann Syndrome: Does it Warrant Different Treatment? J Pediatr Hematol Oncol 2014. http://www.ncbi.nlm.nih.gov/pubmed/24608075.
  • Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, Kwiatkowski JL. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. J Pediatr Hematol Oncol 2015 (in press).
  • Ubogy S, Olson K. The Trauma Symptom Checklist for Children and Misdiagnosis of PTSD in A Youth with Acute Lymphocytic Leukemia: A Brief Report. Journal of Child & Adolescent Trauma 2014:1-3. http://rd.springer.com/article/10.1007/s40653-014-0004-1
  • Vichinsky E. Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology Am Soc Hematol Educ Program 2012;2012:271-5. http://www.ncbi.nlm.nih.gov/pubmed/23233591.
  • Vichinsky E. Advances in the treatment of alpha-thalassemia. Blood Rev 2012;26 Suppl 1:S31-4. http://www.ncbi.nlm.nih.gov/pubmed/22631041.
  • Vichinsky E. Prevalence of medical complications in patients with symptomatic thalassemia syndromes: Baseline findings from the Thalassemia Longitudinal Cohort (TLC) study. 2014 (in process).
  • Vichinsky E. Management of non-transfusion dependent thalassemia (NTDT) & thalassemia intermedia (TI). Clinical Therapeutics 2014 (submitted).
  • Vichinsky E, Neumayr L, Neuropsych_Study. The Safety and Efficacy of Transfusion Compared with Standard Care for the Treatment of Neurologic Dysfunction in Adults with Sickle Cell Disease. 2014 (in process).
  • Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, Boudreaux J, Neufeld EJ, Kenney K, Grant A, Thompson AA, Investigators CDCT. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014;54 4:972-81; quiz 1. http://www.ncbi.nlm.nih.gov/pubmed/23889533.
  • Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CAi. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol 2013;88 12:1068-73. http://www.ncbi.nlm.nih.gov/pubmed/23946212.
  • Vichinsky EP. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology 2012;28 1:20-3. http://www.ncbi.nlm.nih.gov/pubmed/22646146.
  • Vichinsky EP. Clinical Manifestations of a-Thalassemia. Cold Spring Harb Perspect Med 2013;(3) 3; 10.1101/cshperspect.a011742. http://perspectivesmedicine.net/content/early/2013/03/28/cshperspect.a011742.full.pdf+html.
  • Wagner JE, Jr., Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J, Blood, Marrow Transplant Clinical Trials N. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med 2014;371 18:1685-94. http://www.ncbi.nlm.nih.gov/pubmed/25354103.
  • Wahl SK, Garcia A, Hagar W, Gildengorin G, Quirolo K, Vichinsky E. Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion 2012;52 12:2671-6. http://www.ncbi.nlm.nih.gov/pubmed/22519830.
  • Wahl SK, Gildengorin G, Feusner J. Weekend delay in initiation of chemotherapy for acute lymphoblastic leukemia: does it matter? J Pediatr Hematol Oncol 2012;34 1:e8-e11. http://www.ncbi.nlm.nih.gov/pubmed/22146528.
  • Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Grady RW, Vichinsky E, Olivieri N, Trachtenberg F, Alberti D, Fung E, Ames B, Higa A, Harmatz P, Network TCR. Increased leucocyte apoptosis in transfused beta-thalassaemia patients. Br J Haematol 2013;160 3:399-403. http://www.ncbi.nlm.nih.gov/pubmed/23216540.
  • Wun T, Styles L, DeCastro L, Telen MJ, Kuypers F, Cheung A, Kramer W, Flanner H, Rhee S, Magnani JL, Thackray H. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One 2014;9 7:e101301. http://www.ncbi.nlm.nih.gov/pubmed/24988449.
  • Yamashita R, Sobota A, Trachtenberg F, Xu Y, Pakbaz Z, Odame I, Thompson A, Haines D, Kleinert D, Giardina P, Quinn C, Kwiatkowski J, Schilling L, Boudreaux J, Neufeld E. The impact of the child with thalassemia on the family: parental assessments 2014 (in process).
  • Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer 2014;61 1:95-101. http://www.ncbi.nlm.nih.gov/pubmed/23934933.
  • Zhang L, Samad A, Pombo-de-Oliveria MS, Seelo G, Smith MT, Feusner J, Wiemels JL, Buffler PA, Metayer C. Global characteristics of childhood acute promyelocytic leukemia. Blood Reviews 2014;Sep 30 2014. http://www.sciencedirect.com/science/article/pii/S0268960X14000824 .

Editorials:


Letters:

  • Klings ES, Machado RF, Morris CR, Gordeuk VR, Kato GJ, Ataga KI, Castro O, Hsu L, Telen MJ, Krishnamurti L, Steinberg MH, Gladwin MT, Diagnosis ATSCGft, Treatment of Pulmonary Hypertension in Sickle Cell Disease C. Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. Am J Respir Crit Care Med. 2014;190(2):238-40. Epub 2014/07/16. doi: 10.1164/rccm.201404-0733LE. PubMed PMID: 25025360; PubMed Central PMCID: PMC4226058. a href="http://www.atsjournals.org/doi/abs/10.1164/rccm.201404-0733LE#.VLXc-yvF_Tc.
  • Klings ES, Vichinsky EP, Morris CR. Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18. Haematologica 2014;99 2:e19. http://www.ncbi.nlm.nih.gov/pubmed/24497564.
  • Klings ES, Morris CR, Hsu LL, Castro O, Gladwin MT, Mubarak KK. Pulmonary hypertension of sickle cell disease beyond classification constraints. J Am Coll Cardiol 2014;63 25 Pt A:2881-2. http://www.ncbi.nlm.nih.gov/pubmed/24794120.
  • Reddy-Holdcraft S, Mehta PS, Agrawal AK. Paclitaxel for relapsed or recurrent HIV-associated pediatric Kaposi's sarcoma. AIDS 2014;28 5:800-2. http://www.ncbi.nlm.nih.gov/pubmed/24983546.
  • Slone JS, Agrawal AK, Mehta PS, Mazhani L, Motumise K, Anabwani G, Poplack DG. Reply to "Childhood Cancer in Africa". Pediatr Blood Cancer 2014;61 8:1524. http://www.ncbi.nlm.nih.gov/pubmed/24519963.
  • Vichinsky E. Safety of deferasirox in sickle cell disease patients with co-existing liver impairment -- response to Sinakos et. al. British Journal of Haematology 2012;157 4:506-7. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.090 38.x/full.

Abstracts:

  • Abikoff CM, Talano J-A, Keever-Taylor CA, Walters MC, Shenoy S, Moore T, Parsons SK, Dozor AJ, Friedman D, Chitti R, Shi Q, Grossman BJ, Weinberg RS, Morris E, Brand P, Foley S, Militano O, Ayello J, Semidei-Pomales M, Baxter-Lowe LA, Cairo MS. Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 2582. http://www.bloodjournal.org/content/124/21/2582.
  • Adams-Graves P, Heeney M, Mueller B, Baltz B, Yang E, Paley C, Esposito J, McNamara K, Vichinsky E. Treatment patterns and clinical outcomes among patients with sickle cell disease: 24-month follow-up on a 3-year, prospective, non-interventional registry. ASPHO 27th Annual Meeting. Chicago, IL; May 14-17, 2014. Pediatric Blood & Cancer. http://aspho.org/uploads/meetings/2014_Abstracts.pdf.
  • Adisa F, Buchanan I, Morris CR. BiPap use in children with sickle cell disease (SCD) and acute chest syndrome (ACS). 8th Annual Sickle Cell Disease Research and Education Symposium. Miami, FL; April 2014.
  • Aguilar A, Kumar A, Saba J. The effect of sphingadiene treatment on neuroblastoma cells. Sixth CHORI Research Symposium. Oakland, CA: Mar 30, 2012. Children's Hospital & Research Center Oakland.
  • Akinsola B, Hagbom R, Zmitrovich A, Kavanagh P, Ashkouti A, Fletcher A, Vinson N, Simon HK, Fleming A, Jain S, Adisa O, Dampier C, Morris CR. Adding intranasal fentanyl (INF) to the management of sickle cell disease (SCD) vaso-occlusive pain episodes (VOE) at a pediatric emergency department (ED): a quality improvement study. 8th Annual Sickle Cell Disease Research and Education Symposium. Miami, FL; April 2014.
  • Akinsola B, Hagbom R, Zmitrovich A, Kavanagh P, Ashkouti A, Fletcher A, Vinson N, Simon HK, Fleming A, Jain S, Adisa O, Dampier C, Morris CR. More rapid delivery of parenteral analgesia by adding intranasal fentanyl to the management of sickle cell disease vaso-occlusive pain episodes at a pediatric emergency department. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21).
  • Allard H, Weyhmiller MG, Lal A, Fung EB. In-Accuracy Of Bone Density Measurements By DXA In Patients With Hemoglobinopathies and Iron Overload. 54th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 966. http://bloodjournal.hematologylibrary.org/content/12 2/21/966.abstract.
  • Alter BP, Giri N, Calvo KR, Maric I, Arthur DC, Hickstein DD, Hastings CA, Lee MA, Hsu A, Holland SM. Clinically Silent Carriers in Families with Myelodysplastic Syndrome Due to GATA2 Mutations. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.1264. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/1264.
  • Aydinok Y, Galanello R, Viprakasit V, Piga A, Harmatz P, Forni GL, Shah FT, Grace RF, Porter J, Vichinsky E, Wood J, Krishnan S, Zhang P, Abi-Saab W, Rienhoff HY, Neufeld E. The safety, tolerability and efficacy of FBS0701, an iron chelator in clinical development for transfusional iron overload: data from 72 weeks of treatment. 18th Congress of the European Hematology Association. Stockholm, Sweden: June 13-16, 2013. Haematologica.
  • Badawy SM, Pinckney K, Meier ER, Myers K, Black V, Hastings CA, Hilden J, Zweidler-McKay PA, Stork L, Vaiselbuh SR, Johnson TS. First interim analysis of the ASPHO mentoring program. ASPHO 27th Annual Meeting. Chicago, IL; May 14-17, 2014. http://aspho.org/uploads/meetings/2014_Abstracts.pdf.
  • Calloway C, Lee SH, Kim J, Dhillon N, Gildengorin G, Lal A. Mitochondrial Genome Changes As a Measure Of Iron-Induced Mitochondrial Stress In Transfusion-Dependent Thalassemia. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 2256. http://bloodjournal.hematologylibrary.org/content/1 22/21/2256.abstract.
  • Chung J, Feusner J. Utility of hematologic testing for cases of suspected non-accidental trauma. ASPHO 25th Annual Meeting. New Orleans, LA; May 9-12, 2012. Pediatric Blood & Cancer 58(7). http://www.connect2conferenc es.com/aspho4/ws_search/index.php?task=detail&abstract_id=806.
  • Chung J, Fung EB, Feusner JH. A Pilot Study to Assess Alterations in Trace Element Status in Pediatric Patients with Malignancies. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.3183. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/3183.
  • Chung J, Lal A, Vichinsky E. Increasing iron overload following splenectomy in Beta Thalassemia Major. ASPHO Annual Meeting. New Orleans, LA; May 9-12, 2012. Pediatric Blood & Cancer 58(7); p.1076. http://www.connect2conferenc es.com/aspho4/ws_search/index.php?task=detail&abstract_id=842.
  • Delgado EM, Cho CS, Gildengorin G, Leibovich SA, Morris CR. SPeAK Asthma: A study of pediatric adherence and knowledge of asthma. Pediatric Academy Society Annual Meeting. Boston, MA; May 2012.
  • Fens MHAM, Larkin SK, Fitch WL, Scicinski J, Oronsky B, Kuypers FA. Treatment with a Novel Dinitroazetidine, Abdnaz, Improves Nitrite Reductase Activity of Sickle Red Blood Cells. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.3246. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/3246.
  • Fleming A, Jain S, Adisa O, Dampier C, Morris CR. Intranasal fentanyl use improves time to first parenteral analgesia in children with sickle cell disease vaso-occlusive pain episodes at a pediatric emergency department. Pediatric Academy Society Annual Meeting. San Diego, CA; April 2015.
  • Fung E. Low Magnitude Mechanical Stimulation Increases Bone Mass in Adult Patients with Thalassemia: A Pilot Study. Sixth CHORI Research Symposium. Oakland, CA: Mar 30, 2012. Children's Hospital & Research Center Oakland.
  • Fung EB, Killilea DW, Shenvi S, Haines D, Lavrisha L, Flores B, Higa A, Ahmad T, Lal A. Marginal zinc status associated with altered insulin metabolism in patients with thalassemia. 4th International Society for Zinc Biology Meeting. Asilomar, CA; Sep 14-19, 2014. poster presentation, abstract #FF10.
  • Fung EB, Kwiatkowski JL, Huang JN, Gildengorin G, King JC, Queisser AC, Vichinsky EP. Zinc supplementation improves bone density in young adults with thalassemia. 6th International Conference on Children's Bone Health; June 2013. Rotterdam, Netherlands.
  • Fung EB, Reget K, Sawyer A, Haines D, Lal A. Exploring vertebral abnormalities in patients with thalassemia and sickle cell disease. 6th International Conference on Children's Bone Health. Rotterdam, Netherlands; June 2013.
  • Fung EB, Sushrita N, Haines D, Schroepfer C, Lal A. Dietary Intake Insufficient to Support Nutritional Adequacy in Patients with Thalassemia. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 1361-. http://www.bloodjournal.org/content/124/21/1361.
  • Galanello R, Aydinok Y, Piga A, Forni GL, Viprakasit V, Harmatz P, Shah F, Grace R, Vichinsky E, Wood J, Peppe J, Jones A, Rienhoff HY, Neufeld E. A 48 week phase 2 study of the safety, tolerability and efficacy of FBS0701, a novel iron chelator for treatment of transfusional iron overload. 17th Congress of the European Hematology Association. Amsterdam, The Netherlands: June 14-17, 2012. Haematologica 97(s1); #0606. http:// www.ehaweb.org/congress-and-events/18th-congress/previous-congresses-2/abstract-book/eha-17-amsterdam-2012/.
  • Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JGt, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF, Walk Phaast investigators. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012.
  • Gomez E, Calloway C, Hoon Lee S, Kim J, Dhillon N, Gildengoren G, Lal A. Mitochondrial genome changes as a measure of iron-induced mitochondrial stress in transfusion-depedent thalassemia. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 2256. http://bloodjournal.hematologylibrary.org/content/1 22/21/2256.abstract.
  • Hacker NA, King JC, Van Loan MD, Gertz ER, Adams M, Sawyer A, Fung EB. Calcium supplementation during pregnancy improves tibial bone density at one year post-partum in racially diverse women. Experimental Biology, April 2014. San Diego, CA. #14-7168.
  • Haines D. Pain in Thalassemia: Pervasive and Severe. 2nd Meeting of the Worldwide Initiative on Social Studies on Hemoglobinopathies. Atlanta, GA: March 16, 2012. poster presentation.
  • Heeney MM, Baltz B, Adams-Graves P, Yang E, Paley C, Esposito J, McNamara K, Vichinsky E, George A. Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 4890-. http://www.bloodjournal.org/content/124/21/4890.
  • Heeney MM, Mueller BU, Baltz B, Adams-Graves P, Yang E, Paley C, Esposito J, Vichinsky EP. 12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.1010. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/1010.
  • Hoehner C, Hagar RW. A Dedicated Over 50 Sickle Cell Clinic. 6th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Scientific Meeting. Hollywood, Florida; Feb 29-Mar 2, 2012. Am J Hematol 87(7). http://onlinelibrary.wiley.com/doi/10.1002/ajh.23331/abstrac t.
  • Jacobs J. Invasive Pulmonary Aspergillosis in Pediatric Oncology Patients. ASPHO 26th Annual Meeting. Miami, FL; April 24-27, 2013. Pediatric Blood & Cancer 60(S2). http://www.connect2conferen ces.com/aspho4/ws_search/index.php?task=detail&abstract_id=1243.
  • Jubran RF, Leavey PJ, Ritchey AK, Tersak JM, Hastings C, Briones M, Shereck E, Nyquist J, Fisher D. Career development for pediatric hematology/oncology (PHO) fellows: a pilot program. ASPHO 26th Annual Meeting. Miami, FL; April 24-27, 2013. Pediatric Blood & Cancer 60(S2). http://www.connect2conferen ces.com/aspho4/ws_search/index.php?task=detail&abstract_id=1243.
  • Kamani NR, Walters M, Carter S, Brochstein JA, Eapen M, Levine JE, Logan B, Panepinto J, Parikh S, Pulsipher M, Schultz KR, Shenoy S. Unrelated Donor Cord Blood Transplantation For Children With Severe Sickle Cell Disease: Results Of A Phase Ii Study From The Blood And Marrow Transplant Clinical Trials Network. BMT Tandem Meetings. San Diego, CA: Feb. 1-5, 2012. American Society for Blood and Marrow Transplantation #327. http://www.abstracts2view.com/bmt/view.php?nu=ASBMT12L_372
  • Kanathezhath B, Shenvi S, Johl A, Manmohan R, Bhandhal MK, Oh D, Zhou A, Kuypers FA, Walters MC, Ames BN, Suh J. Systemic And Hepatic Thiol Redox Dysregulation In Graft Versus Host Disease. BMT Tandem Meetings. San Diego, CA: Feb. 1-5, 2012. American Society for Blood and Marrow Transplantation #421. http://www.abstracts2view.com/bmt/view.php?nu=ASBMT12L_259.
  • Kanathezhath B, Suh J, Shenvi S, Guo H, Walters M, Ames B. Glutathione Redox Metabolomic Dysregulation Precedes TNF-? Elevation and Predicts Severity of Gvhd in Experimental Transplantation. BMT Tandem Meetings. Salt Lake City, Utah: Feb. 13-17, 2013. American Society for Blood and Marrow Transplantation #438. https://bmt.confex.com/tandem/2013/webprogram/Paper2122.html.
  • Keller SD, Treadwell MJ, Yang M, Werner EM, Hassell KL. Patient reports of health outcomes in sickle cell disease: psychometric properties of the Adult Sickle Cell Quality of Life Measurement System. 2nd Global Congress on Sickle Cell Disease. Rio de Janiero, Brazil: November 11-14, 2014. http://www.hemorio.rj.gov.br/CongressoGSCDN/programa.pdf.
  • Khurana M, Feusner JH, Lee B. Fever at diagnosis of pediatric acute lymphoblastic leukemia (ALL): Are antibiotics really necessary. American Society of Clinical Oncology Annual Meeting. Chicago, Illinois; June 1-5, 2012. Abstract #9553. http://meetinglibrary.asco.org/content/101090-114.
  • Khurana M, Kanathezhath B, Feusner J. Recurrent/refractory metastatic osteosarcoma responds to TRAIL therapy. ASPHO 27th Annual Meeting. Chicago, IL; May 14-17, 2014. http://aspho.org/uploads/meetings/2014_Abstracts.pdf.
  • Khurana M, Vichinsky E, Theil EC. Head-to-head comparison of current clinical iron chelators on cellular ferritin regulation in HEPG2 cell culture model. ASPHO 27th Annual Meeting. Chicago, IL; May 14-17, 2014. http://aspho.org/uploads/meetings/2014_Abstracts.pdf.
  • Klein O, Walters M, George D, Chu R, Goodrich JT, Roman E, Schubert R, Del Toro G. Moyamoya Syndrome Treated With Encephaloduroarteriosynangiosis Followed By Hematopoietic Cell Transplantation In Patients With Sickle Cell Disease. BMT Tandem Meetings. San Diego, CA: Feb. 1-5, 2012. American Society for Blood and Marrow Transplantation #276. http://www.abstracts2view.com/bmt/view.php?nu=ASBMT12L_344
  • Kutlar A, Reid M, Taher AT, Inati A, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Koshy N, Neumayr LD, Malik P, Alvarez OA, Ward R, White JM, Johnson E, Ghalie RG. A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.998. http://abstracts.hematologylibrary.org/cgi/c ontent/abstract/ashmtg;120/21/998.
  • Kutny MA, Alonzo TA, Gerbing RB, Wang Y-C, Fu C, Meshinchi S, Gamis AS, Feusner JH, Gregory J. Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 985-. http://www.bloodjournal.org/content/124/21/985.
  • Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 2306-. http://www.bloodjournal.org/content/124/21/2306.
  • Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 2301-. http://www.bloodjournal.org/content/124/21/2301.
  • Kutny MA, Rajpurkar M, Alonzo TA, Gerbing RB, Gamis AS, Feusner JH, Gregory J. Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 3669-. http://www.bloodjournal.org/content/124/21/3669.
  • Lal A, Patterson L, Goldrich A, Marsh A, Yen K, Bhatnagar A. Detection of elevated end-tidal carbon monoxide concentration in children with sickle cell anemia. PAS/ASPR Joint Meeting. Vancouver, Canada: May 3-6, 2014. Pediatric Academic Societies and Asian Society for Pediatric Research.
  • Lal A, Yen K, Patterson L, Goldrich A, Marsh AM, Bhatnagar A. Elevated End-Tidal Carbon Monoxide Concentration in Children with Sickle Cell Anemia. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 1390-. http://www.bloodjournal.org/content/124/21/1390.
  • Lalefar N, Agarwal R, Porteus M, Kharbanda S, Weinberg K. Bortezomib As a Treatment for Autoimmune Cytopenia After Bone Marrow Transplant. BMT Tandem Meetings. Salt Lake City, Utah: Feb. 13-17, 2013. American Society for Blood and Marrow Transplantation #125.
  • Lalefar N, Ozeran J. Iron Overload in Childhood Cancer. ASPHO 25th Annual Meeting. New Orleans, LA; May 9-12, 2012. Pediatric Blood & Cancer 58(7). http://www.connect2conferenc es.com/aspho4/ws_search/index.php?task=detail&abstract_id=687.
  • Lalefar NR, Walters M. Graft failure after hematopoietic cell transplantation for hemoglobionpathies; successful rescue with alternate donors. Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting. Miami, FL; April 11-14, 2014.
  • Latronica C, Kuypers FA, Rosenfeld H, Larkin SK, Doniger S, Vichinsky E, Morris CR. Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.4752. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/4752.
  • Lazarus SG, Adisa O, Zmitrovich A, Hagbom R, Morris CR. Are we missing the mark? Respiratory signs and symptoms, utilization of chest radiographs (CXRs) and acute chest syndrome (ACS). Pediatric Academy Society Annual Meeting. San Diego, CA; April 2015.
  • Lazarus SG, Adisa O, Zmitrovich A, Hagbom R, Morris CR. Are we missing the mark? Respiratory signs and symptoms, utilization of chest radiographs (CXRs) and acute chest syndrome (ACS). 8th Annual Sickle Cell Disease Research and Education Symposium. Miami, FL; April 2014.
  • Lazarus SG, Adisa O, Zmitrovich A, Hagbom R, Morris CR. Are we missing the mark? Respiratory signs and symptoms, utilization of chest radiographs (CXRs) and acute chest syndrome (ACS). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21).
  • Lee JH, Rademaker AW, Powell BL, Geyer S, Larson RA, Gregory J, Hijiya N, Feusner JH. Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 957-. http://www.bloodjournal.org/content/124/21/957.
  • Lew G, Lu X, Yanofsky R, Rheingold SR, Whitlock J, An Q, Devidas M, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger S, Pulsipher MA. Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 684-. http://www.bloodjournal.org/content/124/21/684.
  • Lew G, Lu X, Yanofsky RA, Rheingold SR, Whitlock JA, Gulig SD, Devidas M, Pulsipher MA, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger SP. The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia: Interim analysis of Children's Oncology Group (COG) protocol AALL0433. ASCO Annual Meeting. Chicago, IL; May 30-June 3, 2014. J Clin Oncol 32:5s(2014 suppl ); abstr 10014.
  • Magnani JL, Kuypers FA, Patton JT, Larkin SK, Styles L, DeCastro LM, Telen MJ, Wun T, Thackray H. Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.87. http://abstracts.hematologylibrary.org/cgi/co ntent/abstract/ashmtg;120/21/87.
  • Majerus EM, Ataga KI, Vichinsky E, Eaton CA, Mazanet R, Nathan DG, Field JJ. NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 2718-. http://www.bloodjournal.org/content/124/21/2718.
  • Marsh A, Feusner J, Cham E. Are bone marrow core biopsies necessary for the initial diagnosis of acute leukemia? ASPHO 25th Annual Meeting. New Orleans, LA; May 9-12, 2012. Pediatric Blood & Cancer 58(7). http://www.connect2conferenc es.com/aspho4/ws_search/index.php?task=detail&abstract_id=783.
  • Marsh AM, Quirolo KC, Golden C, Vichinsky E. Renal Medullary Carcinoma in an Adolescent with Homozygous Hemoglobin SS. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.4774. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/4774.
  • Minor M, Harmatz P, Fuentebella J, Haines D, Lal A, Vichinsky E. Practical management of HCV genotype 1a in B thalassemia major with triple therapy. Viral Hepatitis Congress 2012. Frankfurt, Germany; Sep 7-9 2012. . Journal of Viral Hepatitis 19(s3); 10. <Go to ISI>://WOS:000308584500020
  • Morris CR, Kuypers FA, Lavrisha L, Sweeters N, Stewart M, Ansari M, Neumayr L, Vichinsky EP. Arginine therapy: a novel treatment for children with sickle cell disease and vaso-occlusive pain. First Conference of the International Rare Diseases Research Consortium (IRDiRC). Dublin, Ireland; April 2013.
  • Morris C, Latronica C, Kuypers FA, Rosenfeld H, Larkin SK, Doniger S, Vichinsky E, Shiva S. Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. 8th Annual Sickle Cell Disease Research and Education Symposium. Miami, FL; April 2014.
  • Morris C, Latronica C, Kuypers FA, Rosenfeld H, Larkin SK, Doniger S, Vichinsky E, Shiva S. Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 4690. http://bloodjournal.hematologylibrary.org/content/1 22/21/4690.abstract.
  • Morris CR, Barreda F, Leibovich SA, Rutherford M, Saulys A, Stewart M, Lavrisha L, Vichinsky E, Bell M, Treadwell MJ. Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better! 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.2101. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/2101.
  • Morris CR, Barreda F, Leibovich SA, Rutherford M, Saulys A, Stewart M, Lavrisha L, Vichinsky E, Bell M, Treadwell MJ. Quality improvement initiatives for sickle cell disease pain management in an urban pediatric emergency department significantly improves outcomes. Pediatric Academic Societies Annual Meeting; May 4-7, 2013. Washington, DC. http://www.abstracts2view.com/pas/view.php?nu=PAS13L1_4523. 443.
  • Morris CR, Kim H-Y, Wood JC, Trachtenberg F, Klings ES, Porter JB, Sweeters N, Olivieri NF, Kwiatkowski JL, Singer ST, Taher AT, Neufeld EJ, Thompson AA, Larkin SK, Suh JH, Vichinsky E, Kuypers FA. Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.2122. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/2122.
  • Morris CR, Kim H-Y, Wood JC, Trachtenberg F, Klings ES, Porter JB, Sweeters N, Olivieri NF, Kwiatkowski JL, Singer ST, Taher AT, Neufeld EJ, Thompson AA, Sachdev V, Larkin SK, Suh JH, Kuypers FA, Vichinsky E. Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.1023. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/1023.
  • Morris CR, Kuypers FA, Lavrisha L, Sweeters N, Stewart M, Ansari M, Neumayr L, Vichinsky EP. Randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease and vaso-occlusive pain episodes. NHLBI workshop: Translating new therapeutics for sickle cell disease to the marketplace; August 21, 2013; National Institutes of Health, Bethesda MD.
  • Morris HD, Feusner JH, Wilson KS, Aquino V, Levenson B, Timmons M, Cavalier M, Luu H. Therapy-induced t(11;19)(q23;q13.1) with relapsed acute promyelocytic leukemia. ASPHO 26th Annual Meeting. Miami, FL; April 24-27, 2013. Pediatric Blood & Cancer 60(S2); 895. http://www.connect2conferenc es.com/aspho4/ws_search/index.php?task=detail&abstract_id=895.
  • Morris HD, Feusner JH, Wilson KS, et.al. Therapy-induced t(11;19)(q23;q13.1) with relapsed acute promyelocytic leukemia. Association of Molecular Pathology Annual Meeting. May 2012.
  • Mueller BU, Baltz B, Adams-Graves P, Yang E, Paley C, MSHS JE, MSHS CCRA MK, Vichinsky E. Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 988. http://bloodjournal.hematologylibrary.org/content/12 2/21/988.abstract.
  • Murray L, Walters MC, Chaudhury S, Soni S, Pulsipher MA, Schultz KR, Chan K, Nieder M, Loechelt B, Parikh SH, Kasow KA, Haight A, Hale GA, Connelly J, Andreansky M, Trachtenberg F, Neufeld EJ, Kwiatkowski J, DiFronzo NL, Thompson AA. Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 543. http://bloodjournal.hematologylibrary.org/content/12 2/21/543.abstract.
  • Novelli EM, Delaney K, Axelrod K, Morris CR, Minniti C. Arginine therapy in a patient with Hb-SS disease and refractory leg ulcers. Sickle Cell Disease Association of America Annual Convention. Baltimore, MD; Sept 2012.
  • Paulukonis S, Currier R, Coates TD, Vichinsky E, Feuchtbaum L. Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 4855-. http://www.bloodjournal.org/content/124/21/4855.
  • Paulukonis S, Griffin T, Zhou M, Eckman JR, Hagar R, Bauer Snyder A, Feuchtbaum L, Grant AM, Hulihan M. Sickle Cell Disease Mortality in California and Georgia 2004-2008. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 439-. http://www.bloodjournal.org/content/124/21/439.
  • Porter J, Walter PB, Neumayr LD, Evans P, Weyhmiller MG, Harmatz P, Wood JC, Miller JL, Weiss G, Yuan Q, Wang ZJ, Grosse R, Schoennagel BP, Meerpohl J, Fischer R, Nielsen P, Seifert M, Vichinsky E. Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study). 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 1014. http://bloodjournal.hematologylibrary.org/content/1 22/21/1014.abstract.
  • Porter JB, Walter PB, Neumayr LD, Evans P, Weyhmiller MG, Harmatz P, Wood JC, Miller JL, Weiss G, Yuan Q, Wang ZJ, Grosse R, Schoennagel BP, Meerpohl J, Fischer R, Seifert M, Vichinsky E. Bio-markers of Iron Trafficking and Distribution in Transfusional Overload: Insights from Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia (MCSIO Pilot Study). International BioIron Society Meeting. University College London; April 14-18, 2013.
  • Porter JB, Walter PB, Neumayr LD, Evans P, Weyhmiller MG, Harmatz P, Wood JC, Miller JL, Weiss G, Yuan Q, Wang ZJ, Grosse R, Schoennagel BP, Meerpohl J, Fischer R, Vichinsky E. Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.995. http://abstracts.hematologylibrary.org/cgi/c ontent/abstract/ashmtg;120/21/995.
  • Radhakrishnan K, Talano J, Keever-Taylor C, Bhatia M, Shenoy S, Walters M, Parsons S, Morris E, Baxter-Lowe LA, Cairo MS. Familial Haploidentical (FHI) T-Cell Depleted (TCD) Transplantation In High-Risk Sickle Cell Disease (IND 14359). BMT Tandem Meetings. San Diego, CA: Feb. 1-5, 2012. American Society for Blood and Marrow Transplantation #265. http://www.abstracts2view.com/bmt/view.php?nu=ASBMT12L_203
  • Schiffelers R, Gildengorin G, Kuypers FA, Hoppe C. Microparticles As Biomarkers Of Osteonecrosis Of The Hip In Sickle Cell Disease. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 2226. http://bloodjournal.hematologylibrary.org/content/1 22/21/2226.abstract.
  • Singer ST, Wang J, Suh JH, Killelea D, Ivani K, Oliveros O, Yuan Q, Vichinsky E, Smith J. Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 4707. http://www.bloodjournal.org/content/122/21/4707.
  • Singer ST, Wang J, Yuan Q, Vichinsky E, Smith J, Paley C, Fischer R. Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 4048. https://ash.confex.com/ash/2014/webprogram/Paper75574.html.
  • Suh JH, Kanathezhath B, Swapna S, Guo H, Walters MC, Ames BN. Host Nrf2 -glutathione Redox Dysregulation Precedes TNF-{alpha} Elevation and Predicts Severity of Graft Versus Host Disease in Experimental Transplantation. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.4107. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/4107.
  • Thompson AA, Rasko JE, Hongeng S, Kwiatkowski JL, Schiller G, von Kalle C, Cavazzana M, Leboulch P, Petrusich A, Soni S, Walters MC. Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for ?-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral ??-T87Q -Globin Vector (LentiGlobin BB305 Drug Product). 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 549. Nominated for Best of ASH abstract. http://www.bloodjournal.org/content/124/21/549.
  • Treadwell M, Paulukonis S, Currier B, Hutchinson C, Neumayr L, Vichinsky E, Feuchtbaum L. Population-based study of mental health diagnoses and utilization in sickle cell disease. Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting. Miami, FL; April 11-14, 2014. poster presentation.
  • Treadwell M, Johnson S, Sisler I, Gildengorin G, Medina R, Barreda F, Bitsko M, Smith WR. Evaluation of a sickle cell disease specific readiness for transition assessment. 8th Annual Sickle Cell Disease Research & Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting. Miami, FL. April 11-14, 2014. Journal of Sickle Cell Disease and Hemoglobinopathies 2014(1; doi 10.14223/JSCDH-D-14-00081).
  • Treadwell MJ, Anie K, Asafo M, Creary M, Dennis-Atwi J, grant A, Lamptey M, Ojodu J, Otaigbe A, Yusuf C, Ohene-Frempong K. Development Workshop for a Sickle Cell Counselor Training and Certification Program in Ghana. SCDAA 41st Annual Convention; Sept 25-27, 2013. Baltimore, MD.
  • Treadwell MJ, Barreda F, Payton W, Sydnor V, Murphy W. Using Multidimensional Strategies to Improve Adherence with Iron Chelation Therapies. SCDAA 41st Annual Convention; Sept 25-27, 2013. Baltimore, MD.
  • Treadwell MJ, Bell M, Leibovich SA, Barreda F, Marsh A. Quality improvement initiative improves emergency department care for pediatric patients with sickle cell disease. UCSF Seventh Annual Health Disparities Research Symposium. Oct 23, 2013; San Francisco, CA.
  • Trobaugh-Lotrario AD, Chaiyachati BH, Meyers R, Haberle B, Tomlinson GE, Katzenstein HM, Malogolowkin MH, von Schweinitz D, Krailo MD, Feusner JH. Outcome in congenital hepatoblastoma compared with previously reported data. 2013 ASCO Annual Meeting. May 30 - Jun 3, 2014; Chicago, Illinois. American Society of Clinical Oncology. http://meetinglibrary.asco.org/content/118312-132.
  • Vichinsky E. Fetal hemoglobin and its relationship to CNS disease in hemoglobinopathies. 18th Annual Hemoglobin Switching Conference. Monterey, California; June 7-11, 2012.
  • Vichinsky E, Baltz B, Adams-Graves P, Yang E, Paley C, Esposito J, McNamara K, George A, Heeney MM. Clinical complications in pediatric and adult sickle cell disease. Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference & Exhibit. Portland, OR; Sep 4-6 2014. poster presentation.
  • Vichinsky E, Beshlawy AE, Alzoebie A, Bernaudin F, Koussa S, Chotsampancharoen T, El-Ali A, Arrowsmith C, Martin M, El-Alfy M. Long-term safety and effectiveness of deferasirox (Exjade®) in pediatric patients aged 2–<6 years at enrollment: Interim report from a 5-year observational study. 3rd Pan-European Conference on Haemoglobinopathies and Rare Anaemias. Limassol, Cyprus: Oct 24-26, 2012.
  • Vichinsky E, El-Beshlawy A, Alzoebie A, Bernaudin F, Koussa S, Chotsampancharoen T, El-Ali A, Arrowsmith C, Martin N, El-Alfy M. Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2-<6 Years At Enrollment. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.2125. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/2125.
  • Vichinsky E. Neuropsychological Dysfunction And Neuroimaging Abnormalities In Neurologically Intact Adults with SCD. 6th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Scientific Meeting. Hollywood, Florida; Feb 29-Mar 2, 2012. oral presentation.
  • Vichinsky E. Clinical Aspects of Iron Overload: Causes, Diagnosis, Complications, Treatment, Outcomes. Society for Pediatric Radiology 55th Annual Meeting & Postgraduate Course. San Francisco, California; April 19, 2012. Pediatr Radiol 42, Issue 2 Supplement(2); oral presentation. http://link.springer.com.ucsf.idm.oclc.org/article/10.1007/s00247-012-2356-8/fulltext.html.
  • Walter PB, Harmatz P, Higa A, Ng V, Weyhmiller MG, Evans P, Porter JB, Sweeters N, Price J, Manji A, Killilea D, Lal A, Vichinsky E. Innate Immune Cell Expression of Pattern Recognition Receptors From {beta}-Thalassemia Patients During Intensive Combination Chelation Therapy. 54th Annual Meeting of the American Society of Hematology. Atlanta, GA; Dec 8-11, 2012. Blood 120(21); p.1025. http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;120/21/1025.
  • Walter PB, Harmatz P, Higa A, Ng V, Weyhmiller MG, Evans P, Porter JB, Sweeters N, Price J, Manji A, Killilea D, Lal A, Vichinsky E. Innate Immune Cell Expression of Pattern Recognition Receptors from Transfused Thalassemia Major Patients During Intensive Combination Chelation Therapy. International BioIron Society Meeting. University College London; April 14-18, 2013.
  • Walter PB, Higa A, Ng V, Weyhmiller MG, Slater NR, Evans P, Porter JB, Sweeters N, Price J, Manji A, Killilea D, Lal A, Vichinsky E. Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 3450. http://bloodjournal.hematologylibrary.org/content/1 22/21/3450.abstract.
  • Walter PB, Pakbaz Z, Nemeth E, Ganz T, Porter JB, Evans P, Houston KM, Fischer R, Weyhmiller MG, Herz M, Miller JL, Hagar R, Neumayr LD, Vichinsky E, Harmatz P. Determinants Of Tissue Iron Loading In Transfused and Non-Transfused ?-Thalassemia and Sickle Cell Disease Patients – Biomarkers Of Iron Regulation and Inflammation. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 1017. http://bloodjournal.hematologylibrary.org/content/1 22/21/1017.abstract.
  • Walter PB, Hohman L, Rokeby A, Manocha A, Lum JJ, Lavrisha L, Stewart M, Hagar R, Vichinsky E, Morris CR. The effects of glutamine supplementation on markers of autophagy and apoptosis in peripheral blood mononuclear cells from patients with sickle cell disease. Free Radical Biology and Medicine. Seattle, WA; Nov 2014.
  • Walter PB, Hohman L, Rokeby A, Manocha A, Lum JJ, Lavrisha L, Stewart M, Hagar R, Vichinsky E, Morris CR. The effects of glutamine supplementation on markers of autophagy and apoptosis in peripheral blood mononuclear cells from patients with sickle cell disease. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21).
  • Walters MC, Sandmaier BM, Storb R, D. Flowers ME, Deeg HJ, O'Donnell P, Woolfrey AE, Kiem H-P. Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 4561. http://bloodjournal.hematologylibrary.org/content/1 22/21/4561.abstract.
  • Wang J, Suh JH, Killelea D, Ivani K, Oliveros O, Yuan Q, Vichinsky E, Smith J. Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 4707. http://bloodjournal.hematologylibrary.org/content/1 22/21/4707.abstract.
  • Wang Z, Diaw L, Dizon M, Barr M, Quinn M, Diggs D, Allen D, Seamon C, Oguhebe A, Darbari D, Zhang Y, Gladwin MT, Hutchinson AA, Burdette L, Hoppe C. Admixture In Sickle Cell Disease Defined By Genome Wide Ancestry Informative Markers Varies By Geographic Region In The United States. 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 995. http://bloodjournal.hematologylibrary.org/content/12 2/21/995.abstract.
  • Wang ZJ, Wood JC, Walter PB, Schoennagel BP, Evans P, Neumayr LD, Weyhmiller MG, Harmatz P, Moon JC, Yuan Q, Miller JL, Weiss G, Grosse R, Meerpohl J, Nielsen P, Vichinsky E, Porter JB, Fischer R. Iron distribution assessed by MRI in sickle cell disease, thalassemia and Diamond Blackfan Anemia (MCSIO Pilot Study). International BioIron Society Meeting. University College London; April 14-18, 2013.
  • Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SGE, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS. Recipient HLA-C1 Enhances The Clinical Advantage Of Killer-Cell Immunoglobulin-Like Receptor B haplotype Donors In Myeloablative Unrelated Transplantation For Acute Myelogenous Leukemia. 54th Annual Meeting of the American Society of Hematology. New Orleans, LA; Dec 7-10, 2013. Blood 122(21); 549. http://bloodjournal.hematologylibrary.org/content/12 2/21/549.abstract.
  • Wun T, Telen MJ, Krishnamurti L, McCavit TL, DeCastro LM, Flanner H, Kuypers FA, Larkin SK, Rhee S, Magnani JL, Thackray HM. Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. 56th ASH Annual Meeting and Exposition. San Francisco, CA; Dec 6-9, 2014. Blood 124(21); 2704. http://www.bloodjournal.org/content/124/21/2704.
  • Yang E, Baltz B, Adams-Graves P, Paley C, Esposito B, Vichinsky EP. 12-month follow-up for patients with sickle cell disease in an ongoing 3-year prospective, non-interventional registry trial. SCDAA 41st Annual Convention; Sept 25-27, 2013. Baltimore, MD.
  • Yesim A, Galanello R, Viprakasit V, Piga A, Harmatz P, Forni GL, Shah F, Grace R, Porter J, Vichinsky E, Wood J, Krishnan S, Zhang P, Abi-Saab W, Rienhoff HY, Neufeld E. The safety, tolerability and efficacy of FBS0701, an iron chelator in clinical development for transfusional iron overload: Data from 72 weeks of treatment. 18th Congress of the European Hematology Association. Stockholm, Sweden; June 13-16, 2013.


The following sections are not yet complete and include only a small portion of our lectures, presentations and honors..



Awards and Honors:

Invited Lectures:

  • Hastings C. Clinical experience with cyclodextrin INDs in NPC. NNPDF; Aug 8, 2013 Baltimore, MD.
  • Lal A. Non-Transfusion-Dependent Thalassemia. Cooley's Anemia Foundation Patient Conference; June 28, 2013; , Philadelphia, PA.
  • Lal A. Thalassemia: Genetic Diversity and Current Management Strategies. Postgraduate Institute of Medical Education and Research Invited Lecture in Department of Hematology; Sept 20, 2013, Chandigarh, India.
  • Lal A. Beta Thalassemia Major. Glan-Sagar Institute of Medical Sciences Grand Rounds; Sept 24, 2013, Chandigarh, India.
  • Lal A. Thalassemia Intermedia. UC Davis, Dept of Pediatrics, Grand Rounds; Feb 3, 2014; Davis, CA.
  • Morris CR. Alterations in the arginine metabolome in hemoglobinopathies. The Gordon Nitric Oxide Research Conference; Feb. 2015; Ventura, CA, Oakland, CA.
  • Morris CR. Arginine, Glutamine, Nitric Oxide, and Antioxidant Therapies in Sickle Cell Disease. International Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Morris CR. Arginine, Glutamine, Nitric Oxide, and Antioxidant Therapies in Sickle Cell Disease. International Advanced Workshop on Sickle Cell Disease; Oct. 18, 2012; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Morris CR. Arginine dysregulation in sickle cell disease.Visiting Professor lecture; March 22, 2012; University of Illinois, Chicago IL.
  • Morris CR. Arginine dysregulation in sickle cell disease.Visiting Professor lecture, Vascular Medicine Institute; March 22, 2012; University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Morris CR. Arginine metabolome in sickle cell disease: rationale for arginine therapy. Sept 10, 2014; University of Pittsburgh School of Medicine, Pittsburgh PA.
  • Morris CR. Arginine therapy in sickle cell disease: the next PECARN trial. Sept 10, 2014; University of Pittsburgh School of Medicine, Pittsburgh PA.
  • Morris CR. Asthma in sickle cell disease. Cellular and molecular mechanisms of acute lung injury in sickle cell disease; Nov 4, 2013; U01 Kick-off Conference, Atlanta GA.
  • Morris CR. Clinical studies in thalassemia. Einstein 2012 Red Cell Symposium; Oct. 5, 2012; Bronx, NY.
  • Morris CR. Global arginine bioavailability ratio: a novel biomarker of early mortality in sicle cell disease. Emory Program in Cardiovascular Outcomes Research and Epidemiology (EPICOR); June 7, 2013; Emory University School of Medicine, Atlanta GA.
  • Morris CR. Lung injury in sickle cell disease. International Advanced Workshop on Sickle Cell Disease; Oct. 18, 2012; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Morris CR. Lung Injury and New Clinical Practice Guidelines. International Advanced Workshop on Sickle Cell Disease; October 23-24, 2014; Children's Hospital & Research Center Oakland, CA, Oakland, CA.
  • Morris CR. New strategies for the treatment of pain in children with sickle cell disease. Grand Rounds; Jan. 21, 2015; Emory University School of Medicine.
  • Morris CR. Pulmonary Hypertension in Sickle Cell Disease. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Morris CR. Randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease and vaso-occlusive pain episodes. NHLBI workshop: Translating new therapeutics for sickle cell disease to the marketplace; August 21, 2013; National Institutes of Health, Bethesda MD.
  • Treadwell MJ. Emerging Services for Haemoglobinopathies: Teaching the Community about Program Evaluation. 7th Annual Sickle Cell and Thalassemia Advanced Conference; Oct 3-5, 2013 King's Health Partners Academic Health Sciences Centre for London, London, UK.
  • Treadwell MJ. Issues in the Successful Transition from Pediatric to Adult Care in Sickle Cell Disease. Annual Sickle Cell Symposium; Sept 2013; Koma Linda University, Loma Linda, CA.
  • Treadwell MJ. Psychobiological reactivity in sickle cell disease. Southern California Clinical Translational Science Institute, Jan 2013; University of Southern California, Los Angeles, CA.
  • Treadwell MJ, Anie K, Asafo M, Creary M, Dennis-Atwi J, Grant A, Lamptey M, Ojodu J, Otaigbe A, Yusuf C, Ohene-Frempong K. Using qualitative and quantitative strategies to inform development of a sickle cell counselor training and certification program. 7th Annual Sickle Cell and Thalassemia Advanced Conference; Oct 3-5, 2013; King's Health Partners Academic Health Sciences Centre for London, London, UK.
  • Vichinsky E. Hemoglobinopathies: New Frontiers and Insights. Dec 8-12, 2012, ASH Education Program Chair. ASH Annual Meeting and Exposition. Atlanta, GA.;oral presentation.
  • Vichinsky E. Clarice Reid, MD Lecture: The Future of Sickle Cell Disease Research. SCDAA 41st Annual Convention; Sept 25-27, 2013, Baltimore, MD.
  • Vichinsky E. Cerebrovascular Disease in Adults with Sickle Cell Disease. 7th Sickle Cell in Focus Conference; June 2013, London, UK.
  • Vichinsky E. Sickle Cell and Thalassemia. 2013 Highlights of ASH in Latin America; April 25-26, 2013, Santiago, Chile.
  • Vichinsky E. NBIA Background and TIRCON Trial Overview. NBIA Family Conference; April 4-6, 2013, San Antonio, Texas.
  • Vichinsky E. Hemoglobin Disorders and Iron Overload. Feb 13-15, 2013, Bayer Hemoglobinopathies Life Sciences Workshop. Miami, FL;oral presentation.
  • Vichinsky E. The Complex Pathophysiology of the Hemoglobinopathies: Guiding Us to Innovative Challenges. Presidential Symposium; May 14-17, 2014, 27th Annual ASPHO Meeting, Chicago, IL.

Presentations:

  • Fung EB. Video WebCast for "Think Zinc" Study: Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. American Journal of Clinical Nutrition, November 2013, http://www.scivee.tv/node/61490.
  • Hagar W. Pain Management in Sickle Cell Disease: Acute and Chronic. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Hoppe C. Emerging Therapies and Clinical Trials of Sickle Cell Disease and Vasculopathy. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Kelly S. Alloimmunization in Sickle Cell Disease. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Lal A. Approaches to Chelation. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Lal A. Combined Chelation Therapy. Bayer Hemoglobinopathy Meeting; Feb. 13, 2013, San Francisco, CA.
  • Lal A. Chelation. Thalassemia Patient and Family Conference, Jan 18, 2014, Oakland CA.
  • Lal A. Iron Chelation Therapy. Patient Conference; Feb. 10, 2014; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Levine L. Progress. "Evening Under the Stars", May 3, 2014, Oakland CA. https://www.youtube.com/watch?v=UF5EeH01CNs.
  • Levine L. Live to Give. "Evening Under the Stars", May 2, 2013, Oakland CA. https://www.youtube.com/watch?v=NgA4cxMJ7t8.
  • Marsh A. Hemoglobin F Modulation: Hydroxyurea In 2013. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Quirolo KC. Overview of Transfusion Therapy in Sickle Cell Disease. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Treadwell M. Clinical Dilemmas and their Solutions. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Treadwell M. Issues in Transition from Pediatric to Adult Care in Sickle Cell Disease. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Treadwell M. The Northern California Network of Care for Sickle Cell Disease and the Public Health Research, Epidemiology & Surveillance in Hemoglobinopathies (PHRESH) Project; California Sickle Cell Resources (CaSickleCell.org); Blood Centers of the Pacific. Sickle Cell Disease Public Service Announcement [Video]: 510 Media LLC; Aug 21, 2013. https://www.youtube.com/watch?v=vhynwbIGQug.
  • Vichinsky E. Clinical aspects of iron overload. April 19, 2012. Society for Pediatric Radiology Annual Meeting;oral presentation.
  • Vichinsky E. Neuropsychological Dysfunction And Neuroimaging Abnormalities In Neurologically Intact Adults with SCD. Feb 29-Mar 2, 2012, 6th Annual Sickle Cell Disease Research and Educational Symposium & Annual National SCD Scientific Meeting;oral presentation.
  • Vichinsky E. Role of Transfusion Therapy for Complications Beyond Neurological Complications & the Management of Intermittently-Transfused Patients. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Vichinsky E, Baltz B, Adams-Graves P, Yang E, Paley C, Esposito J, McNamara K, George A, Heeney MM. Clinical complications in pediatric and adult sickle cell disease. Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference & Exhibit. Portland, OR; Sep 4-6 2014. poster presentation.
  • Vichinsky E. Thalassemia Research and Care Update. Thalassemia Patient and Family Conference, Jan 18, 2014, Oakland CA.
  • Walters M. Bone Marrow/Stem Cell Transplant/Gene Therapy. Thalassemia Patient and Family Conference, Jan 18, 2014, Oakland CA.
  • Walters MC. Alternate Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.
  • Walters MC. Gene Therapy and Hemoglobinopathies. Advanced Workshop on Sickle Cell Disease; Nov 14-15, 2013; Children's Hospital & Research Center Oakland, Oakland, CA.

Profiles:

updated 22 Jan 2015


UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 • Phone: (510) 428-3000